Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

Trial Design and Participants VRC 614 was a phase 1, open-label, dose-escalation clinical trial. The primary objectives of the trial were to evaluate the safety and side-effect profile of L9LS administered at intravenous doses of 1, 5, and 20 mg per kilogram of body weight and at a subcutaneous dose of 5 mg per kilogram. …

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Read More »